Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Uppsala University · Clinical Research Institute · +12 more institutions
Indexed incrossrefpubmed
Abstract
Background
Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel.
Methods
In this multicenter, double-blind, randomized trial, we compared ticagrelor (180-mg loading dose, 90 mg twice daily thereafter) and clopidogrel (300-to-600-mg loading dose, 75 mg daily thereafter) for the prevention of cardiovascular events in 18,624 patients admitted to the hospital with an acute coronary syndrome, with or without ST-segment elevation.
Citation impact
7,056
total citations
- FWCI
- 229.13
- Percentile
- 100%
- References
- 35
Citations per year
Authors
16Topics & keywords
Topics
Keywords
- Ticagrelor
- Medicine
- Clopidogrel
- P2Y12
- Myocardial infarction
- Internal medicine
- Acute coronary syndrome
- Stroke (engine)
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.